Expansion Therapeutics, a company founded on the basis of Dr. Matt Disney’s research, has received $55.3M in Series A financing to develop therapies for DM and other diseases.
MDF, in partnership with the Wyck Foundation and other donors, has announced $700,000 in funding to increase the number of sites in the Myotonic Dystrophy Clinical Research Network (DMCRN), and enable critically important new research.
MDF has been awarded a $1M donation by an anonymous family in the DM community to launch development of gene editing technology to pursue the search for a cure for DM1.
Discovery of the holy grail for DM therapy development-- drug registration endpoints -- lies in the dogged pursuit and sharing of natural history data.
NINDS announces its intent to issue Funding Opportunity Announcements to support analytical validation of identified candidate biomarkers.
NINDS has renewed an initiative to provide set-aside funds for basic research grants that miss their regular payline.
NIH announces intent to reissue a Funding Opportunity Announcement for the Rare Disease Clinical Research Network competition.